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OBJECTIVES: In a context of ageing populations and rising
health care costs, it is important to explore health care costs at
the end of life. The aim of this study is to quantify drug costs of
patients who died at the University Hospitals Leuven in Belgium
in 2006. METHODS: This retrospective, cross-sectional cost
analysis measured drug costs related to the hospital stay during
which patients died at University Hospitals Leuven in 2006.
Drugs were classiﬁed at level 1 of the Anatomical Therapeutic
Chemical (ATC) classiﬁcation system. Drug resource utilisation
was valued at unit costs pertaining to University Hospitals
Leuven. The price year was 2007. Associations between drug
costs and patient characteristics were investigated using the
Mann-Whitney U-test. RESULTS: In total, 1462 patients died
during their hospital stay at University Hospitals Leuven in 2006.
Total drug costs related to their ﬁnal hospital stay amounted to
2,970,457€. Median costs per patient were 576€ (0€–48,236€).
There was no association between drug costs per patient and
gender (p = 0.063). Median costs per patient were higher for
patients aged under 68 years (837€) than for patients aged over
68 years (470€) (p < 0.001). Total drug costs were made up of
blood and blood organs (ATC level B, 33% of costs), anti-
infectives for systemic use (ATC level J, 31% of costs), nervous
system drugs (ATC level N, 7% of costs), systemic hormonal
preparations (ATC level H, 3% of costs), cardiovascular drugs
(ATC level C, 2% of costs), and various other drugs (24% of
costs). The 15 patients with the most expensive hospital stays
generated 16% of total drug costs. CONCLUSION: Drug costs
related to the hospital stay during which patients died were
substantial. Drug resource utilization primarily related to blood
and blood organs, and anti-infectives for systemic use.
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OBJECTIVES: Published cost effectiveness analyses of IVF are
generally based on clinical trial data, although costs and out-
comes may not be representative of usual practice. This analysis
evaluated the costs and outcomes of rFSH use in usual practice in
the UK. METHODS: Subjects were randomly selected from all
women undergoing IVF or Intracytoplasmic Sperm Injection
(ICSI) treatment between 2001–2007 at a single centre serving
NHS and private patients in England. Women were treated with
rFSH (Puregon, Organon) for ovarian stimulation, predomi-
nantly as part of an antagonist protocol. Per cycle rates of clinical
and ongoing pregnancy and live birth were calculated. The costs
of rFSH were calculated from pharmacy dispensing data at 2007
UK prices. RESULTS: Four hundred, nineteen women were
included, reporting 601 treatment cycles. Mean age was 36.3
years (range 21–49). The causes of infertility were: male factor
(43%); female factor (38%); unexplained or other (19%). The
clinical pregnancy rate was 35.9% (95% CI 32.2–40.0%),
ongoing pregnancy rate 25.0% (21.5–28.4%) and live birth rate
20.8% (17.7–24.1%). Mean duration of ovarian stimulation was
9.4 days (9.3–9.6 days). The mean per cycle rFSH dose pre-
scribed was 1816 units (1775–1863) and dispensed was 1960
units (1897–2012). Mean cost of rFSH per cycle was 661
(640–679). CONCLUSION: UK guidelines assume the
average per cycle FSH dose is 1750–2625, cost of drugs is1000
and total cost of the cycle is 2771. By substituting FSH use
derived from clinical practice, the cost per cycle could be reduced
by 12%. Further research will extend this work to other centres
and settings.
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OBJECTIVES: To generate national estimates of inpatient costs,
length of stay (LOS), and probability of death among US pedi-
atric (17 years) hospitalizations for blunt or penetrating
trauma, stratiﬁed by injury severity and trauma center designa-
tion of the admitting facility. METHODS: Discharge data from
the 2002 HCUP Nationwide Inpatient Sample were analyzed for
55,561 pediatric hospital admissions (unweighted n = 11,566)
for blunt or penetrating trauma. An injury severity score (ISS)
was calculated for each admission using the ICDMAP90 soft-
ware; 4 mutually exclusive categories corresponding to increas-
ing severity were identiﬁed. Data on admitting facilities’ trauma
center designation were obtained from the American Hospital
Association. Stays for patients admitted from or transferred to
another inpatient facility were excluded. Weighted estimates of
costs, LOS, and probability of death were calculated for each
stay. RESULTS: Most admissions (57.5%) were for low severity
injuries (ISS = 0–9); critical injuries (ISS = 25+) represented 8.5%
of admissions. Nearly half (44.9%) of all admissions were to
non-trauma centers; Level I, II, and III/IV trauma centers repre-
sented 29.9%, 19.5%, and 4.3% of admissions, respectively.
Overall, inpatient costs increased substantially with injury sever-
ity, ranging from $7,803 for low severity admissions to $34,135
for critical admissions. LOS and probability of death also
increased from low to critical injury severity (3.0 to 10.7 days,
0.5% to 23.9%, respectively). Costs, LOS, and probability of
death decreased from Level I to III/IV trauma centers ($14,745 to
$9,170, 5.1 to 3.6 days, 3.3% to 2.9%, respectively); for non-
trauma centers, these outcomes were $12,267, 4.6 days, and
2.6%, respectively. CONCLUSION: This is one of few studies to
quantify differences in inpatient costs and outcomes for trau-
matic injury among pediatric patients across levels of injury
severity and trauma center designation, in a multi-payer US
population. Substantial variation was observed for all outcomes
evaluated. These results may help decision makers allocate
resources appropriately.
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OBJECTIVES: To evaluate the cost-effectiveness of Magnetic
Resonance Image-Guided Focused Ultrasound (MRgFUS) com-
pared to alternative treatment options for uterine ﬁbroids from a
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